MED Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Medifast Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 26.69 USD 2.93%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast MED stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MED is 25.5 USD with a low forecast of 25.25 USD and a high forecast of 26.25 USD.

MED Lowest Forecast

Wall Street Target

MED Average Forecast

Wall Street Target

MED Highest Forecast

Wall Street Target

5% Downside

4% Downside

2% Downside

The latest public price target was made on Apr 30, 2024 by Linda Bolton Weiser from D.A. Davidson , who expects MED stock to drop by 6% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Linda Bolton Weiser D.A. Davidson	25 USD Downside 6%	4 days ago Apr 30, 2024	Medifast (MED) PT Lowered to $25 at DA Davidson StreetInsider
Stephanie Wissink Jefferies	150 USD Upside 462%	10 months ago Jun 5, 2023	Wall Street's Most Accurate Analysts Say Hold These 3 Defensive Stocks With Over 6% Dividend Yields Benzinga
Linda Bolton Weiser D.A. Davidson	94 USD Upside 252%	1 year ago Apr 6, 2023	Check Out 3 High-Yielding Dividend Stocks In Defensive Sector From Wall Street's Most Accurate Analysts Benzinga

Price Target	25 USD
Upside/Downside	6%

Price Target	150 USD
Upside/Downside	462%

Price Target	94 USD
Upside/Downside	252%

FitLife Brands Inc

84% Downside

By-health Co Ltd

47% Upside

Shiseido Co Ltd

15% Upside

Natural Beauty Bio-Technology Ltd

105% Upside

FitLife Brands Inc

84% Downside

By-health Co Ltd

47% Upside

Shiseido Co Ltd

15% Upside

Natural Beauty Bio-Technology Ltd

105% Upside

Procter & Gamble Hygiene and Health Care Ltd

12% Upside

Honest Company Inc

63% Upside

Perfect Group Corp Ltd

29% Upside

Noevir Holdings Co Ltd

12% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Medifast Inc's revenue is 19%. The projected CAGR for the next 2 years is -16%.

19%

-16%

0%

What are analyst estimates?

Operating Income
Forecast

For the last 8 years the compound annual growth rate for Medifast Inc's operating income is 20%. The projected CAGR for the next 2 years is -44%.

20%

-44%

1%

What are analyst estimates?

Net Income
Forecast

For the last 8 years the compound annual growth rate for Medifast Inc's net income is 22%. The projected CAGR for the next 2 years is -41%.

22%

-41%

7%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for MED is 25.5 USD with a low forecast of 25.25 USD and a high forecast of 26.25 USD.

For the last 8 years the compound annual growth rate for Medifast Inc's revenue is 19%. The projected CAGR for the next 2 years is -16%.

For the last 8 years the compound annual growth rate for Medifast Inc's operating income is 20%. The projected CAGR for the next 2 years is -44%.

For the last 8 years the compound annual growth rate for Medifast Inc's net income is 22%. The projected CAGR for the next 2 years is -41%.

Join more than 134,100+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.